Onsdag 28 Oktober | 18:12:59 Europe / Stockholm

All ägardata du vill ha finns i Holdings!

Redeye Initiates Coverage of ISR Holding

2022-05-05 07:35:00

Redeye initiates coverage of ISR Immune System Regulation Holding AB, a Swedish biotech company developing an HIV treatment and a nasally inhaled COVID-19 vaccine, both of which we believe can prompt a paradigm shift in the current standard of care. ISR awaits clinical phase IIa trial data for its HIV study and approval to initiate a clinical phase I/II trial for its COVID-19 vaccine. We view the current share price as an attractive entry opportunity for long-term-oriented investors.

Read more and download the Research Report.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/